Non-Alcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Metabolic Syndrome Research

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent global liver condition linked to metabolic syndrome, affecting 17-46% of adults.
• NAFLD encompasses a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis, with NASH progression driving advanced liver disease.
• Diagnosis of steatosis relies on imaging, whereas NASH confirmation requires liver biopsy.

Purpose of the Study:

• To review the current understanding of NAFLD, its progression, diagnostic challenges, and treatment strategies.
• To highlight the need for effective pharmacological interventions for NASH and the potential role of existing agents.
• To emphasize the recent recommendation for screening NAFLD and advanced fibrosis in type 2 diabetes patients.

Main Methods:

• Literature review of NAFLD prevalence, associations, and disease spectrum.
• Analysis of current diagnostic methods for steatosis and NASH.
• Evaluation of established and emerging therapeutic approaches for NAFLD and NASH.

Main Results:

• NAFLD is a significant cause of chronic liver disease, associated with obesity, type 2 diabetes, and genetic factors.
• Lifestyle modification and weight reduction are primary treatments, but no specific pharmacological NAFLD treatment is FDA-approved.
• Vitamin E and pioglitazone may be considered for biopsy-proven NASH, with new antifibrotic and anti-inflammatory agents in trials.

Conclusions:

• NAFLD management primarily involves lifestyle changes, with ongoing research for targeted pharmacological therapies.
• Screening for NAFLD and advanced fibrosis in type 2 diabetes patients is increasingly advocated.
• Further research into antifibrotic and anti-inflammatory agents is crucial for advancing NASH treatment.